Responding to the announcement by the European Medicines Agency (EMA) that it is to temporarily scale back and suspend some activities, Sir Hugh Taylor, co-chair of the Brexit Health Alliance, said:
“It is concerning that the EMA is already beginning to scale back and suspend activities as a result of loss of staff and expertise – this could negatively affect patients in the UK and across Europe.
“We have previously warned that the Brexit-related relocation of the EMA could impact on its ability to carry out its work.
“The UK Government still wishes to participate in the EMA, but negotiating a deal that protects patients in Europe as well as UK remains a challenge – and a priority.
“As the Brexit Health Alliance, we will continue to point to those issues affecting health which will have an impact on patient safety and which could so easily be ignored in wider discussions. Public health, research, and supply of medicines and equipment are all at risk if we get this wrong.”
Notes to editors
- The Brexit Health Alliance brings together the NHS, medical research, industry, patients and public health organisations to safeguard the interests of patients and the healthcare and research they rely on as the UK moves into negotiations with the EU.
- The Brexit Health Alliance will complement the work of the Cavendish Coalition, which is concerned with the staffing and workforce implications in health and social care of the UK leaving the EU. The Cavendish Coalition is led by NHS Employers, which is part of the NHS Confederation. For more information, visit http://www.nhsconfed.org/BrexitHealthAlliance
Media team contact details
Please direct media queries to NHS Confederation head of communications Dan Keel, on 020 7799 8637 or email@example.com. Alternatively, please contact media and communications manager Neil Durham, on 020 7799 8671 or firstname.lastname@example.org.